Sirion Therapeutics has announced that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).
The two new clinical programs are designed to evaluate ST-601 (difluprednate) as a potential therapy for the treatment of anterior uveitis and ST-603 (cyclosporine) as a potential therapy for the treatment of dry eye syndrome. The addition of these clinical programs brings the company's active clinical programs to five. Sirion's aim is to provide a diverse product offering for the treatment of debilitating ophthalmic diseases and conditions.
Dr. Roger Vogel, Sirion's Chief Medical Officer, commented, "We are pleased with the progress we have made in all of our clinical programs. We have built an excellent network of experienced and professional clinical investigators that have afforded us our success to date."
"I am proud of the hard work and innovative spirit of our R&D staff," said Barry Butler, Sirion's President and Chief Executive Officer. "Our clinical and regulatory teams have done an outstanding job with the planning and execution of our development programs to date."